Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tarsus Pharmaceuticals excels in Q4 earnings, eyes expansion opportunities

Tarsus Pharmaceuticals delivered strong financial results and positive feedback on their products. While facing challenges in payer contracts and physician adoption, they are well-positioned to capitalize on opportunities for expansion and innovation.

Tarsus Pharmaceuticals reports robust Q1 performance and eyes market expansion

Tarsus Pharmaceuticals (TARS) delivered strong Q1 results driven by XDEMVY sales and positive clinical data, with plans for further growth and optimization. While facing market challenges and seasonality, the company is focused on capitalizing on opportunities for expansion and market education. TARS aims to enhance gross-to-net margins, increase prescriber adoption, and navigate the evolving healthcare landscape.

Tarsus Pharmaceuticals excels in Q3, eyes European expansion and pipeline advancement

Tarsus Pharmaceuticals demonstrated robust performance in Q3 2024, with strong sales, expanded market access, and positive clinical data, positioning the company for continued success.
While facing challenges in market competition and international expansion, Tarsus can capitalize on opportunities in evidence generation, pipeline advancement, and patient education to drive future growth.
Overall, Tarsus Pharmaceuticals shows promise in maintaining its market position, driving product adoption, and exploring new avenues for growth and innovation in the pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enrollment of Galatea, a Phase 2a trial evaluating TP-04 for Rosacea, with topline data expected in 1H 2024 Strengthened balance sheet with $100 million public equity offering in August 2023 IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the second quarter ended June 30, 2023, and recent business achievements.

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the pricing of an underwritten public offering of 5,714,285 shares of its common stock at a public offering price of $17.50 per share, before underwriting discounts and commissions. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 857,142 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close August 4, 2023, subject to the satisfaction of customary closing conditions.

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

Tarsus Pharmaceuticals, Inc. achieved FDA approval of XDEMVY for the treatment of patients with Demodex blepharitis; XDEMVY for this indication could offer $1 billion + peak net sales potential. Results from the phase 2 study using XDEMVY [TP-03] for the treatment of patients with Meibomian Gland Disease is expected in the 2nd half of 2023. Results from the phase 2 study using TP-05 for the prevention of Lyme Disease expected in the 2nd half of 2023.

Tarsus Pharma: Despite Dropping After FDA Approval, 2 Catalysts Still Remain

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S.

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

Tarsus specializes in treating eye and skin disorders. The company is still in the clinical stage but has several late-stage pipeline candidates.

Why Shares of Tarsus Pharmaceuticals Are Up Thursday

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?

IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a virtual event to provide an overview on the commercialization strategy, plans and progress for TP-03, the Company's potential treatment for Demodex blepharitis.

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus, will participate in an in-person Fireside Chat at the Jefferies Global Healthcare Conference taking place in New York, NY. on Wednesday, June 7 at 11:30am PT / 2:30pm ET.

Tarsus to Present at the Jefferies Global Healthcare Conference

Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S.

Tarsus Launches “Don't Freak Out. Get Checked Out.

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus and Jeff Farrow, Chief Financial and Strategy Officer, will participate in 1:1 meetings at the Bank of America 2023 Healthcare Conference taking place in Las Vegas, Nev. on Wednesday, May 10th 2023.

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests.

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex blepharitis in anticipation of TP-03 August 25, 2023 PDUFA

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

Tarsus ran two pivotal trials in an eye indication. Data was excellent and shows that TP-03 will help patients.

Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential

Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective December 19, 2022.

Tarsus Added to NASDAQ Biotechnology Index

Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates

New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors

Tarsus Announces Transition Plans for Board of Directors

Mr. Morrison brings over 40 years of financial and operational expertise in life sciences

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S.

News for Tarsus Pharmaceuticals Stock (TARS)